From Immunosuppression to Immunomodulation: Current Principles and Future Strategies
- 30 August 2013
- journal article
- review article
- Published by S. Karger AG in Pathobiology
- Vol. 80 (6), 275-281
- https://doi.org/10.1159/000346960
Abstract
Over the last few decades, tremendous progress has been made in understanding the mechanisms of immune responses. This progress has also led to a more detailed knowledge of the processes leading to the loss of self-tolerance and the destruction of self-tissue in the case of autoimmune diseases, the effector mechanism involved in transplant allograft rejection as well as the driving factors in exacerbated inflammatory disorders. Despite this progress, the challenge still remains to selectively interfere with immune responses responsible for autoimmunity or transplant rejection while keeping an intact response to infectious agents. To date, such a selective interference is still difficult to achieve, as highlighted by the fact that an overall increased risk for infections and malignancy continues to be the most frequent side effect of the currently used immunosuppressive principles. Nevertheless, although discovered several decades ago, many of the ‘first-generation' immunosuppressive principles such as steroids, methotrexate and cyclosporin A are still in clinical use, demonstrating the therapeutic value of these drugs for the patients that are in need. In this review, the author describes the mode of action of the currently most used immunosuppressive agents (not attempting to cover all principles that are available) and expands on recent activities in the discovery and development of novel immunomodulatory principles.Keywords
This publication has 27 references indexed in Scilit:
- Kinase inhibitors: a new class of antirheumatic drugsDrug Design, Development and Therapy, 2012
- Cyclosporine: A ReviewJournal of Transplantation, 2012
- Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapiesClinical and Experimental Immunology, 2011
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 2010
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and UveitisScience Translational Medicine, 2010
- Effects of Natalizumab on Circulating B Cells, T Regulatory Cells and Natural Killer CellsEuropean Neurology, 2010
- Methotrexate—how does it really work?Nature Reviews Rheumatology, 2010
- The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell ActivationJournal of Pharmacology and Experimental Therapeutics, 2009
- Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligandsSteroids, 2008
- Daclizumab induction in solid organ transplantationExpert Opinion on Biological Therapy, 2004